nodes	percent_of_prediction	percent_of_DWPC	metapath
Tetrabenazine—Bronchitis—Lisinopril—systemic scleroderma	0.00446	0.00446	CcSEcCtD
Tetrabenazine—Insomnia—Pentoxifylline—systemic scleroderma	0.00444	0.00444	CcSEcCtD
Tetrabenazine—Nervousness—Captopril—systemic scleroderma	0.00443	0.00443	CcSEcCtD
Tetrabenazine—Sweating—Mycophenolic acid—systemic scleroderma	0.0044	0.0044	CcSEcCtD
Tetrabenazine—Dyspnoea—Pentoxifylline—systemic scleroderma	0.00438	0.00438	CcSEcCtD
Tetrabenazine—Somnolence—Pentoxifylline—systemic scleroderma	0.00437	0.00437	CcSEcCtD
Tetrabenazine—Dysuria—Lisinopril—systemic scleroderma	0.00433	0.00433	CcSEcCtD
Tetrabenazine—Dry mouth—Mometasone—systemic scleroderma	0.00432	0.00432	CcSEcCtD
Tetrabenazine—Upper respiratory tract infection—Lisinopril—systemic scleroderma	0.00431	0.00431	CcSEcCtD
Tetrabenazine—Orthostatic hypotension—Mycophenolate mofetil—systemic scleroderma	0.00429	0.00429	CcSEcCtD
Tetrabenazine—Decreased appetite—Pentoxifylline—systemic scleroderma	0.00427	0.00427	CcSEcCtD
Tetrabenazine—Urinary tract disorder—Leflunomide—systemic scleroderma	0.00426	0.00426	CcSEcCtD
Tetrabenazine—Urethral disorder—Leflunomide—systemic scleroderma	0.00423	0.00423	CcSEcCtD
Tetrabenazine—Constipation—Pentoxifylline—systemic scleroderma	0.0042	0.0042	CcSEcCtD
Tetrabenazine—Bradycardia—Mycophenolic acid—systemic scleroderma	0.00419	0.00419	CcSEcCtD
Tetrabenazine—Depression—Lisinopril—systemic scleroderma	0.00412	0.00412	CcSEcCtD
Tetrabenazine—Urinary tract disorder—Mycophenolic acid—systemic scleroderma	0.00407	0.00407	CcSEcCtD
Tetrabenazine—Dysphagia—Mycophenolate mofetil—systemic scleroderma	0.00406	0.00406	CcSEcCtD
Tetrabenazine—Feeling abnormal—Pentoxifylline—systemic scleroderma	0.00405	0.00405	CcSEcCtD
Tetrabenazine—Urethral disorder—Mycophenolic acid—systemic scleroderma	0.00404	0.00404	CcSEcCtD
Tetrabenazine—Eye disorder—Leflunomide—systemic scleroderma	0.00403	0.00403	CcSEcCtD
Tetrabenazine—Cardiac disorder—Leflunomide—systemic scleroderma	0.00401	0.00401	CcSEcCtD
Tetrabenazine—Ecchymosis—Prednisone—systemic scleroderma	0.00397	0.00397	CcSEcCtD
Tetrabenazine—Sweating—Lisinopril—systemic scleroderma	0.00396	0.00396	CcSEcCtD
Tetrabenazine—Bronchitis—Mycophenolate mofetil—systemic scleroderma	0.0039	0.0039	CcSEcCtD
Tetrabenazine—Body temperature increased—Pentoxifylline—systemic scleroderma	0.00388	0.00388	CcSEcCtD
Tetrabenazine—Dysarthria—Methotrexate—systemic scleroderma	0.00388	0.00388	CcSEcCtD
Tetrabenazine—Eye disorder—Mycophenolic acid—systemic scleroderma	0.00385	0.00385	CcSEcCtD
Tetrabenazine—Cardiac disorder—Mycophenolic acid—systemic scleroderma	0.00382	0.00382	CcSEcCtD
Tetrabenazine—Dysuria—Mycophenolate mofetil—systemic scleroderma	0.0038	0.0038	CcSEcCtD
Tetrabenazine—Dry mouth—Captopril—systemic scleroderma	0.0038	0.0038	CcSEcCtD
Tetrabenazine—Mental disorder—Leflunomide—systemic scleroderma	0.00378	0.00378	CcSEcCtD
Tetrabenazine—Dyspnoea—Mometasone—systemic scleroderma	0.00378	0.00378	CcSEcCtD
Tetrabenazine—Bradycardia—Lisinopril—systemic scleroderma	0.00378	0.00378	CcSEcCtD
Tetrabenazine—Confusional state—Captopril—systemic scleroderma	0.00375	0.00375	CcSEcCtD
Tetrabenazine—Angiopathy—Mycophenolic acid—systemic scleroderma	0.00374	0.00374	CcSEcCtD
Tetrabenazine—Decreased appetite—Mometasone—systemic scleroderma	0.00368	0.00368	CcSEcCtD
Tetrabenazine—Urinary tract disorder—Lisinopril—systemic scleroderma	0.00366	0.00366	CcSEcCtD
Tetrabenazine—Fatigue—Mometasone—systemic scleroderma	0.00365	0.00365	CcSEcCtD
Tetrabenazine—Urethral disorder—Lisinopril—systemic scleroderma	0.00364	0.00364	CcSEcCtD
Tetrabenazine—Depression—Mycophenolate mofetil—systemic scleroderma	0.00361	0.00361	CcSEcCtD
Tetrabenazine—Mental disorder—Mycophenolic acid—systemic scleroderma	0.00361	0.00361	CcSEcCtD
Tetrabenazine—Leukopenia—Azathioprine—systemic scleroderma	0.00356	0.00356	CcSEcCtD
Tetrabenazine—Asthenia—Pentoxifylline—systemic scleroderma	0.00352	0.00352	CcSEcCtD
Tetrabenazine—Tension—Mycophenolic acid—systemic scleroderma	0.00352	0.00352	CcSEcCtD
Tetrabenazine—Nervousness—Mycophenolic acid—systemic scleroderma	0.00348	0.00348	CcSEcCtD
Tetrabenazine—Hypotension—Captopril—systemic scleroderma	0.00348	0.00348	CcSEcCtD
Tetrabenazine—Sweating—Mycophenolate mofetil—systemic scleroderma	0.00347	0.00347	CcSEcCtD
Tetrabenazine—Insomnia—Captopril—systemic scleroderma	0.00337	0.00337	CcSEcCtD
Tetrabenazine—Angiopathy—Lisinopril—systemic scleroderma	0.00337	0.00337	CcSEcCtD
Tetrabenazine—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.00336	0.00336	CcSEcCtD
Tetrabenazine—Leukopenia—Leflunomide—systemic scleroderma	0.00336	0.00336	CcSEcCtD
Tetrabenazine—Diarrhoea—Pentoxifylline—systemic scleroderma	0.00336	0.00336	CcSEcCtD
Tetrabenazine—Tremor—Mycophenolic acid—systemic scleroderma	0.00336	0.00336	CcSEcCtD
Tetrabenazine—Body temperature increased—Mometasone—systemic scleroderma	0.00335	0.00335	CcSEcCtD
Tetrabenazine—Dyspnoea—Captopril—systemic scleroderma	0.00332	0.00332	CcSEcCtD
Tetrabenazine—Ecchymosis—Methotrexate—systemic scleroderma	0.00331	0.00331	CcSEcCtD
Tetrabenazine—Bradycardia—Mycophenolate mofetil—systemic scleroderma	0.00331	0.00331	CcSEcCtD
Tetrabenazine—Somnolence—Captopril—systemic scleroderma	0.00331	0.00331	CcSEcCtD
Tetrabenazine—Agitation—Mycophenolic acid—systemic scleroderma	0.00329	0.00329	CcSEcCtD
Tetrabenazine—Mental disorder—Lisinopril—systemic scleroderma	0.00325	0.00325	CcSEcCtD
Tetrabenazine—Dizziness—Pentoxifylline—systemic scleroderma	0.00325	0.00325	CcSEcCtD
Tetrabenazine—Decreased appetite—Captopril—systemic scleroderma	0.00323	0.00323	CcSEcCtD
Tetrabenazine—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.00321	0.00321	CcSEcCtD
Tetrabenazine—Leukopenia—Mycophenolic acid—systemic scleroderma	0.00321	0.00321	CcSEcCtD
Tetrabenazine—Fatigue—Captopril—systemic scleroderma	0.00321	0.00321	CcSEcCtD
Tetrabenazine—Anxiety—Leflunomide—systemic scleroderma	0.00319	0.00319	CcSEcCtD
Tetrabenazine—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.00319	0.00319	CcSEcCtD
Tetrabenazine—Osteoarthritis—Prednisone—systemic scleroderma	0.00318	0.00318	CcSEcCtD
Tetrabenazine—Constipation—Captopril—systemic scleroderma	0.00318	0.00318	CcSEcCtD
Tetrabenazine—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.00318	0.00318	CcSEcCtD
Tetrabenazine—Tension—Lisinopril—systemic scleroderma	0.00317	0.00317	CcSEcCtD
Tetrabenazine—Skin disorder—Azathioprine—systemic scleroderma	0.00315	0.00315	CcSEcCtD
Tetrabenazine—Nervousness—Lisinopril—systemic scleroderma	0.00314	0.00314	CcSEcCtD
Tetrabenazine—Dry mouth—Leflunomide—systemic scleroderma	0.00313	0.00313	CcSEcCtD
Tetrabenazine—Vomiting—Pentoxifylline—systemic scleroderma	0.00312	0.00312	CcSEcCtD
Tetrabenazine—Headache—Pentoxifylline—systemic scleroderma	0.00308	0.00308	CcSEcCtD
Tetrabenazine—Feeling abnormal—Captopril—systemic scleroderma	0.00307	0.00307	CcSEcCtD
Tetrabenazine—Anxiety—Mycophenolic acid—systemic scleroderma	0.00304	0.00304	CcSEcCtD
Tetrabenazine—Asthenia—Mometasone—systemic scleroderma	0.00304	0.00304	CcSEcCtD
Tetrabenazine—Irritability—Prednisone—systemic scleroderma	0.00304	0.00304	CcSEcCtD
Tetrabenazine—Eye disorder—Mycophenolate mofetil—systemic scleroderma	0.00304	0.00304	CcSEcCtD
Tetrabenazine—Hypotension—Azathioprine—systemic scleroderma	0.00303	0.00303	CcSEcCtD
Tetrabenazine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.00303	0.00303	CcSEcCtD
Tetrabenazine—Tremor—Lisinopril—systemic scleroderma	0.00303	0.00303	CcSEcCtD
Tetrabenazine—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.00302	0.00302	CcSEcCtD
Tetrabenazine—Nervous system disorder—Leflunomide—systemic scleroderma	0.00301	0.00301	CcSEcCtD
Tetrabenazine—Dry mouth—Mycophenolic acid—systemic scleroderma	0.00298	0.00298	CcSEcCtD
Tetrabenazine—Skin disorder—Leflunomide—systemic scleroderma	0.00298	0.00298	CcSEcCtD
Tetrabenazine—Hyperhidrosis—Leflunomide—systemic scleroderma	0.00296	0.00296	CcSEcCtD
Tetrabenazine—Confusional state—Mycophenolic acid—systemic scleroderma	0.00295	0.00295	CcSEcCtD
Tetrabenazine—Angiopathy—Mycophenolate mofetil—systemic scleroderma	0.00295	0.00295	CcSEcCtD
Tetrabenazine—Body temperature increased—Captopril—systemic scleroderma	0.00294	0.00294	CcSEcCtD
Tetrabenazine—Nausea—Pentoxifylline—systemic scleroderma	0.00292	0.00292	CcSEcCtD
Tetrabenazine—Diarrhoea—Mometasone—systemic scleroderma	0.0029	0.0029	CcSEcCtD
Tetrabenazine—Leukopenia—Lisinopril—systemic scleroderma	0.00289	0.00289	CcSEcCtD
Tetrabenazine—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00287	0.00287	CcSEcCtD
Tetrabenazine—Hypotension—Leflunomide—systemic scleroderma	0.00287	0.00287	CcSEcCtD
Tetrabenazine—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.00285	0.00285	CcSEcCtD
Tetrabenazine—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00284	0.00284	CcSEcCtD
Tetrabenazine—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00283	0.00283	CcSEcCtD
Tetrabenazine—Tension—Mycophenolate mofetil—systemic scleroderma	0.00278	0.00278	CcSEcCtD
Tetrabenazine—Insomnia—Leflunomide—systemic scleroderma	0.00277	0.00277	CcSEcCtD
Tetrabenazine—Nervousness—Mycophenolate mofetil—systemic scleroderma	0.00275	0.00275	CcSEcCtD
Tetrabenazine—Anxiety—Lisinopril—systemic scleroderma	0.00274	0.00274	CcSEcCtD
Tetrabenazine—Dyspnoea—Leflunomide—systemic scleroderma	0.00273	0.00273	CcSEcCtD
Tetrabenazine—Hypotension—Mycophenolic acid—systemic scleroderma	0.00273	0.00273	CcSEcCtD
Tetrabenazine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00273	0.00273	CcSEcCtD
Tetrabenazine—Vomiting—Mometasone—systemic scleroderma	0.00269	0.00269	CcSEcCtD
Tetrabenazine—Dry mouth—Lisinopril—systemic scleroderma	0.00269	0.00269	CcSEcCtD
Tetrabenazine—Feeling abnormal—Azathioprine—systemic scleroderma	0.00268	0.00268	CcSEcCtD
Tetrabenazine—Asthenia—Captopril—systemic scleroderma	0.00267	0.00267	CcSEcCtD
Tetrabenazine—Decreased appetite—Leflunomide—systemic scleroderma	0.00267	0.00267	CcSEcCtD
Tetrabenazine—Osteoarthritis—Methotrexate—systemic scleroderma	0.00266	0.00266	CcSEcCtD
Tetrabenazine—Confusional state—Lisinopril—systemic scleroderma	0.00266	0.00266	CcSEcCtD
Tetrabenazine—Headache—Mometasone—systemic scleroderma	0.00265	0.00265	CcSEcCtD
Tetrabenazine—Tremor—Mycophenolate mofetil—systemic scleroderma	0.00265	0.00265	CcSEcCtD
Tetrabenazine—Insomnia—Mycophenolic acid—systemic scleroderma	0.00265	0.00265	CcSEcCtD
Tetrabenazine—Fatigue—Leflunomide—systemic scleroderma	0.00264	0.00264	CcSEcCtD
Tetrabenazine—Constipation—Leflunomide—systemic scleroderma	0.00262	0.00262	CcSEcCtD
Tetrabenazine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00261	0.00261	CcSEcCtD
Tetrabenazine—Somnolence—Mycophenolic acid—systemic scleroderma	0.0026	0.0026	CcSEcCtD
Tetrabenazine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.0026	0.0026	CcSEcCtD
Tetrabenazine—Body temperature increased—Azathioprine—systemic scleroderma	0.00257	0.00257	CcSEcCtD
Tetrabenazine—Skin disorder—Lisinopril—systemic scleroderma	0.00256	0.00256	CcSEcCtD
Tetrabenazine—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00255	0.00255	CcSEcCtD
Tetrabenazine—Diarrhoea—Captopril—systemic scleroderma	0.00255	0.00255	CcSEcCtD
Tetrabenazine—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00254	0.00254	CcSEcCtD
Tetrabenazine—Irritability—Methotrexate—systemic scleroderma	0.00254	0.00254	CcSEcCtD
Tetrabenazine—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.00253	0.00253	CcSEcCtD
Tetrabenazine—Feeling abnormal—Leflunomide—systemic scleroderma	0.00253	0.00253	CcSEcCtD
Tetrabenazine—Fatigue—Mycophenolic acid—systemic scleroderma	0.00252	0.00252	CcSEcCtD
Tetrabenazine—Nausea—Mometasone—systemic scleroderma	0.00252	0.00252	CcSEcCtD
Tetrabenazine—Ataxia—Methotrexate—systemic scleroderma	0.0025	0.0025	CcSEcCtD
Tetrabenazine—Constipation—Mycophenolic acid—systemic scleroderma	0.0025	0.0025	CcSEcCtD
Tetrabenazine—Hypotension—Lisinopril—systemic scleroderma	0.00246	0.00246	CcSEcCtD
Tetrabenazine—Dizziness—Captopril—systemic scleroderma	0.00246	0.00246	CcSEcCtD
Tetrabenazine—Depression—Prednisone—systemic scleroderma	0.00245	0.00245	CcSEcCtD
Tetrabenazine—Body temperature increased—Leflunomide—systemic scleroderma	0.00242	0.00242	CcSEcCtD
Tetrabenazine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00241	0.00241	CcSEcCtD
Tetrabenazine—Breast disorder—Methotrexate—systemic scleroderma	0.0024	0.0024	CcSEcCtD
Tetrabenazine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.0024	0.0024	CcSEcCtD
Tetrabenazine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00239	0.00239	CcSEcCtD
Tetrabenazine—Insomnia—Lisinopril—systemic scleroderma	0.00238	0.00238	CcSEcCtD
Tetrabenazine—Vomiting—Captopril—systemic scleroderma	0.00237	0.00237	CcSEcCtD
Tetrabenazine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.00236	0.00236	CcSEcCtD
Tetrabenazine—Dyspnoea—Lisinopril—systemic scleroderma	0.00235	0.00235	CcSEcCtD
Tetrabenazine—Somnolence—Lisinopril—systemic scleroderma	0.00234	0.00234	CcSEcCtD
Tetrabenazine—Headache—Captopril—systemic scleroderma	0.00233	0.00233	CcSEcCtD
Tetrabenazine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.00233	0.00233	CcSEcCtD
Tetrabenazine—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.00231	0.00231	CcSEcCtD
Tetrabenazine—Decreased appetite—Lisinopril—systemic scleroderma	0.00229	0.00229	CcSEcCtD
Tetrabenazine—Fatigue—Lisinopril—systemic scleroderma	0.00227	0.00227	CcSEcCtD
Tetrabenazine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00226	0.00226	CcSEcCtD
Tetrabenazine—Constipation—Lisinopril—systemic scleroderma	0.00225	0.00225	CcSEcCtD
Tetrabenazine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00224	0.00224	CcSEcCtD
Tetrabenazine—Bradycardia—Prednisone—systemic scleroderma	0.00224	0.00224	CcSEcCtD
Tetrabenazine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00223	0.00223	CcSEcCtD
Tetrabenazine—Diarrhoea—Azathioprine—systemic scleroderma	0.00222	0.00222	CcSEcCtD
Tetrabenazine—Nausea—Captopril—systemic scleroderma	0.00221	0.00221	CcSEcCtD
Tetrabenazine—Asthenia—Leflunomide—systemic scleroderma	0.0022	0.0022	CcSEcCtD
Tetrabenazine—Feeling abnormal—Lisinopril—systemic scleroderma	0.00217	0.00217	CcSEcCtD
Tetrabenazine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.00216	0.00216	CcSEcCtD
Tetrabenazine—Dysuria—Methotrexate—systemic scleroderma	0.00215	0.00215	CcSEcCtD
Tetrabenazine—Dizziness—Azathioprine—systemic scleroderma	0.00215	0.00215	CcSEcCtD
Tetrabenazine—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.00214	0.00214	CcSEcCtD
Tetrabenazine—Asthenia—Mycophenolic acid—systemic scleroderma	0.0021	0.0021	CcSEcCtD
Tetrabenazine—Diarrhoea—Leflunomide—systemic scleroderma	0.0021	0.0021	CcSEcCtD
Tetrabenazine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00209	0.00209	CcSEcCtD
Tetrabenazine—Body temperature increased—Lisinopril—systemic scleroderma	0.00208	0.00208	CcSEcCtD
Tetrabenazine—Vomiting—Azathioprine—systemic scleroderma	0.00206	0.00206	CcSEcCtD
Tetrabenazine—Eye disorder—Prednisone—systemic scleroderma	0.00206	0.00206	CcSEcCtD
Tetrabenazine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00206	0.00206	CcSEcCtD
Tetrabenazine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.00205	0.00205	CcSEcCtD
Tetrabenazine—Drowsiness—Methotrexate—systemic scleroderma	0.00205	0.00205	CcSEcCtD
Tetrabenazine—Depression—Methotrexate—systemic scleroderma	0.00204	0.00204	CcSEcCtD
Tetrabenazine—Headache—Azathioprine—systemic scleroderma	0.00203	0.00203	CcSEcCtD
Tetrabenazine—Dizziness—Leflunomide—systemic scleroderma	0.00203	0.00203	CcSEcCtD
Tetrabenazine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.00201	0.00201	CcSEcCtD
Tetrabenazine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.002	0.002	CcSEcCtD
Tetrabenazine—Angiopathy—Prednisone—systemic scleroderma	0.002	0.002	CcSEcCtD
Tetrabenazine—Constipation—Mycophenolate mofetil—systemic scleroderma	0.00197	0.00197	CcSEcCtD
Tetrabenazine—Sweating—Methotrexate—systemic scleroderma	0.00197	0.00197	CcSEcCtD
Tetrabenazine—Vomiting—Leflunomide—systemic scleroderma	0.00195	0.00195	CcSEcCtD
Tetrabenazine—Dizziness—Mycophenolic acid—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Tetrabenazine—Mental disorder—Prednisone—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Tetrabenazine—Nausea—Azathioprine—systemic scleroderma	0.00193	0.00193	CcSEcCtD
Tetrabenazine—Headache—Leflunomide—systemic scleroderma	0.00192	0.00192	CcSEcCtD
Tetrabenazine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.0019	0.0019	CcSEcCtD
Tetrabenazine—Asthenia—Lisinopril—systemic scleroderma	0.00189	0.00189	CcSEcCtD
Tetrabenazine—Vomiting—Mycophenolic acid—systemic scleroderma	0.00186	0.00186	CcSEcCtD
Tetrabenazine—Headache—Mycophenolic acid—systemic scleroderma	0.00183	0.00183	CcSEcCtD
Tetrabenazine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.00183	0.00183	CcSEcCtD
Tetrabenazine—Nausea—Leflunomide—systemic scleroderma	0.00182	0.00182	CcSEcCtD
Tetrabenazine—Urinary tract disorder—Methotrexate—systemic scleroderma	0.00182	0.00182	CcSEcCtD
Tetrabenazine—Urethral disorder—Methotrexate—systemic scleroderma	0.0018	0.0018	CcSEcCtD
Tetrabenazine—Diarrhoea—Lisinopril—systemic scleroderma	0.0018	0.0018	CcSEcCtD
Tetrabenazine—Agitation—Prednisone—systemic scleroderma	0.00176	0.00176	CcSEcCtD
Tetrabenazine—Dizziness—Lisinopril—systemic scleroderma	0.00174	0.00174	CcSEcCtD
Tetrabenazine—Nausea—Mycophenolic acid—systemic scleroderma	0.00174	0.00174	CcSEcCtD
Tetrabenazine—Eye disorder—Methotrexate—systemic scleroderma	0.00172	0.00172	CcSEcCtD
Tetrabenazine—Cardiac disorder—Methotrexate—systemic scleroderma	0.00171	0.00171	CcSEcCtD
Tetrabenazine—Vomiting—Lisinopril—systemic scleroderma	0.00168	0.00168	CcSEcCtD
Tetrabenazine—Angiopathy—Methotrexate—systemic scleroderma	0.00167	0.00167	CcSEcCtD
Tetrabenazine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00166	0.00166	CcSEcCtD
Tetrabenazine—Headache—Lisinopril—systemic scleroderma	0.00165	0.00165	CcSEcCtD
Tetrabenazine—Anxiety—Prednisone—systemic scleroderma	0.00163	0.00163	CcSEcCtD
Tetrabenazine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.00162	0.00162	CcSEcCtD
Tetrabenazine—Mental disorder—Methotrexate—systemic scleroderma	0.00161	0.00161	CcSEcCtD
Tetrabenazine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00158	0.00158	CcSEcCtD
Tetrabenazine—Nausea—Lisinopril—systemic scleroderma	0.00157	0.00157	CcSEcCtD
Tetrabenazine—Nervous system disorder—Prednisone—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Tetrabenazine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00153	0.00153	CcSEcCtD
Tetrabenazine—Skin disorder—Prednisone—systemic scleroderma	0.00152	0.00152	CcSEcCtD
Tetrabenazine—Hyperhidrosis—Prednisone—systemic scleroderma	0.00151	0.00151	CcSEcCtD
Tetrabenazine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.00147	0.00147	CcSEcCtD
Tetrabenazine—Headache—Mycophenolate mofetil—systemic scleroderma	0.00145	0.00145	CcSEcCtD
Tetrabenazine—Leukopenia—Methotrexate—systemic scleroderma	0.00143	0.00143	CcSEcCtD
Tetrabenazine—Insomnia—Prednisone—systemic scleroderma	0.00142	0.00142	CcSEcCtD
Tetrabenazine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.00137	0.00137	CcSEcCtD
Tetrabenazine—Decreased appetite—Prednisone—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Tetrabenazine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.00136	0.00136	CcSEcCtD
Tetrabenazine—Fatigue—Prednisone—systemic scleroderma	0.00135	0.00135	CcSEcCtD
Tetrabenazine—Constipation—Prednisone—systemic scleroderma	0.00134	0.00134	CcSEcCtD
Tetrabenazine—Confusional state—Methotrexate—systemic scleroderma	0.00132	0.00132	CcSEcCtD
Tetrabenazine—Feeling abnormal—Prednisone—systemic scleroderma	0.00129	0.00129	CcSEcCtD
Tetrabenazine—Nervous system disorder—Methotrexate—systemic scleroderma	0.00128	0.00128	CcSEcCtD
Tetrabenazine—Skin disorder—Methotrexate—systemic scleroderma	0.00127	0.00127	CcSEcCtD
Tetrabenazine—Hyperhidrosis—Methotrexate—systemic scleroderma	0.00126	0.00126	CcSEcCtD
Tetrabenazine—Body temperature increased—Prednisone—systemic scleroderma	0.00124	0.00124	CcSEcCtD
Tetrabenazine—Hypotension—Methotrexate—systemic scleroderma	0.00122	0.00122	CcSEcCtD
Tetrabenazine—Insomnia—Methotrexate—systemic scleroderma	0.00118	0.00118	CcSEcCtD
Tetrabenazine—Dyspnoea—Methotrexate—systemic scleroderma	0.00117	0.00117	CcSEcCtD
Tetrabenazine—Somnolence—Methotrexate—systemic scleroderma	0.00116	0.00116	CcSEcCtD
Tetrabenazine—Decreased appetite—Methotrexate—systemic scleroderma	0.00114	0.00114	CcSEcCtD
Tetrabenazine—Fatigue—Methotrexate—systemic scleroderma	0.00113	0.00113	CcSEcCtD
Tetrabenazine—Asthenia—Prednisone—systemic scleroderma	0.00112	0.00112	CcSEcCtD
Tetrabenazine—Feeling abnormal—Methotrexate—systemic scleroderma	0.00108	0.00108	CcSEcCtD
Tetrabenazine—Diarrhoea—Prednisone—systemic scleroderma	0.00107	0.00107	CcSEcCtD
Tetrabenazine—Dizziness—Prednisone—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Tetrabenazine—Body temperature increased—Methotrexate—systemic scleroderma	0.00103	0.00103	CcSEcCtD
Tetrabenazine—Vomiting—Prednisone—systemic scleroderma	0.000995	0.000995	CcSEcCtD
Tetrabenazine—Headache—Prednisone—systemic scleroderma	0.00098	0.00098	CcSEcCtD
Tetrabenazine—Asthenia—Methotrexate—systemic scleroderma	0.000938	0.000938	CcSEcCtD
Tetrabenazine—Nausea—Prednisone—systemic scleroderma	0.00093	0.00093	CcSEcCtD
Tetrabenazine—Diarrhoea—Methotrexate—systemic scleroderma	0.000895	0.000895	CcSEcCtD
Tetrabenazine—Dizziness—Methotrexate—systemic scleroderma	0.000865	0.000865	CcSEcCtD
Tetrabenazine—Vomiting—Methotrexate—systemic scleroderma	0.000832	0.000832	CcSEcCtD
Tetrabenazine—Headache—Methotrexate—systemic scleroderma	0.000819	0.000819	CcSEcCtD
Tetrabenazine—Nausea—Methotrexate—systemic scleroderma	0.000777	0.000777	CcSEcCtD
